PMID- 9645897
OWN - NLM
STAT- MEDLINE
DCOM- 19980714
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 81
IP  - 12
DP  - 1998 Jun 15
TI  - Effect of beta-blocker therapy in patients with coronary artery disease in New 
      York Heart Association classes II and III. The Bezafibrate Infarction Prevention 
      (BIP) Study Group.
PG  - 1455-60
AB  - The aim of the study was to investigate the effect of beta-blocker treatment on a 
      large cohort of patients with coronary artery disease in functional classes II 
      and III according to the New York Heart Association (NYHA) classification. Among 
      11,575 patients with coronary artery disease screened for participation, but not 
      included in the Bezafibrate Infarction Prevention (BIP) study, 3,225 (28%) were 
      in NYHA classes II and III. In the latter group of patients we compared the 
      prognosis of 1,109 (34%) treated with beta blockers with 2,116 counterparts not 
      receiving beta-blocker therapy. After a mean follow-up of 4 years, all-cause and 
      cardiac mortality rates were significantly lower among beta-blocker users, 9% and 
      5%, respectively, than among beta-blocker nonusers, 17% and 11%, respectively (p 
      <0.01 for both). After multivariate adjustment, treatment with beta blockers was 
      associated with a lower all-cause mortality risk (hazards ratio [HR] 0.62, 95% 
      confidence interval [CI] 0.49 to 0.78), and a lower cardiac mortality risk (HR = 
      0.61, 95% CI 0.45 to 0.83) than was no treatment with a beta blocker. Lower total 
      mortality risk was noted among patients in NYHA class II (HR 0.63, 95% CI 0.48 to 
      0.82) and in NYHA class III (HR 0.57, 95% CI 0.37 to 0.87) as well as in patients 
      with (HR 0.62, 95% CI 0.48 to 0.81) or without (HR 0.70, 95% CI 0.45 to 1.09) a 
      previous myocardial infarction. We conclude that beta-blocker therapy in coronary 
      patients in NYHA classes II or III is safe and associated with a lower risk for 
      all-cause and cardiac mortality.
FAU - Haim, M
AU  - Haim M
AD  - The Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer, 
      Israel.
FAU - Shotan, A
AU  - Shotan A
FAU - Boyko, V
AU  - Boyko V
FAU - Reicher-Reiss, H
AU  - Reicher-Reiss H
FAU - Benderly, M
AU  - Benderly M
FAU - Goldbourt, U
AU  - Goldbourt U
FAU - Behar, S
AU  - Behar S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Adrenergic beta-Antagonists)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aged
MH  - Cohort Studies
MH  - Coronary Disease/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Odds Ratio
MH  - Risk
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 1998/06/30 00:00
MHDA- 1998/06/30 00:01
CRDT- 1998/06/30 00:00
PHST- 1998/06/30 00:00 [pubmed]
PHST- 1998/06/30 00:01 [medline]
PHST- 1998/06/30 00:00 [entrez]
AID - S0002914998002057 [pii]
AID - 10.1016/s0002-9149(98)00205-7 [doi]
PST - ppublish
SO  - Am J Cardiol. 1998 Jun 15;81(12):1455-60. doi: 10.1016/s0002-9149(98)00205-7.